Intra-Cellular Therapies Inc [ITCI] stock prices are up 2.17% to $86.96 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ITCI shares have gain 4.63% over the last week, with a monthly amount glided 4.24%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on September 06, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $92 from $68. Previously, Robert W. Baird started tracking the stock with Outperform rating on January 03, 2024, and set its price target to $83. On December 11, 2023, TD Cowen initiated with a Outperform rating and assigned a price target of $75 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $80 on April 20, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $49 on August 22, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $74. In a note dated June 14, 2022, UBS initiated an Buy rating and provided a target price of $75 on this stock.
The stock price of Intra-Cellular Therapies Inc [ITCI] has been fluctuating between $62.78 and $93.45 over the past year. Currently, Wall Street analysts expect the stock to reach $93.33 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $86.96 at the most recent close of the market. An investor can expect a potential return of 7.33% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
The Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 613.73M for trailing twelve months, representing a surge of 39.00%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 85.05 points at the first support level, and at 83.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 87.97, and for the 2nd resistance point, it is at 88.98.
Ratios To Look Out For
It’s worth pointing out that Intra-Cellular Therapies Inc [NASDAQ:ITCI]’s Current Ratio is 7.66. In addition, the Quick Ratio stands at 7.51 and the Cash Ratio stands at 2.8. Considering the valuation of this stock, the price to sales ratio is 15.02, the price to book ratio is 8.05.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman and CEO, that happened on Dec 04 ’24 when 51000.0 shares were sold. Chairman and CEO, Mates Sharon completed a deal on Dec 05 ’24 to sell 51697.0 shares. Meanwhile, Officer Mates Sharon bought 51697.0 shares on Dec 05 ’24.
